x

Posted 13 February, 2023

Frequency Therapeutics, Inc. appointed Christopher Loose, Ph.D. as new CEO

Nasdaq:FREQ appointed new Chief Executive Officer Christopher Loose, Ph.D. in a 8-K filed on 13 February, 2023.


  On February 11, 2023, the Company's Board of Directors appointed Christopher Loose, Ph.D., as Interim Chief Executive Officer while David Lucchino, the Company's President and Chief Executive Officer, is on a temporary medical leave of absence after being hospitalized with bacterial meningitis.  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of Frequency Therapeutics, Inc.
Health Care/Life Sciences • Biotechnology
Korro Bio, Inc. is an RNA editing company, which engages in the discovery and development of genetic medicines. The company was founded by Nessan Bermingham, Jean-Francois Formela, Joshua Rosenthal, and Andrew Fraley in 2018 and is headquartered in Cambridge, MA.
Market Cap
$401M
View Company Details
Frequency Therapeutics, Inc. by TradingView
Relevant filing section
Item 5.02. 
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. 


Chief Executive Officer Appointment 

On February 11, 2023, the Company's Board of Directors appointed Christopher Loose, Ph.D., as Interim Chief Executive Officer while David Lucchino, the Company's President and Chief Executive Officer, is on a temporary medical leave of absence after being hospitalized with bacterial meningitis. Mr. Lucchino is expected to make a full recovery. Dr. Loose will also continue to serve as the Company's Chief Scientific Officer. The Company expects Mr. Lucchino will resume his position in full as Chief Executive Officer upon his return. 

Dr. Loose, age 42, co-founded the Company and has served as its Chief Scientific Officer since January 2016. Prior to founding the Company, Dr. Loose co-founded Semprus with Mr. Lucchino and Dr. Robert Langer and served as its Chief Technology Officer from June 2007 until its acquisition by Teleflex in June 2012. At Semprus, he led the technology team in the development through regulatory clearance of medical products designed to reduce infection and clotting. Prior to Semprus, Dr. Loose worked as a chemical engineer at Merck Research Labs. In 2011, Dr. Loose was awarded the inaugural Peter Strauss Entrepreneurial Award from the Hertz Foundation. From 2014 to 2021, Dr. Loose served as an Associate Professor Adjunct of Urology at the Yale School of Medicine and Executive Director of Yale University's Center for Biomedical Innovation and Technology, and he continues to serve as a Lecturer in Yale School of Management. Dr. Loose holds a Ph.D. in Chemical Engineering from MIT and a BSE in Chemical Engineering summa cum laude from Princeton University. 


Chief Development Officer Departure 

As part of the Reduction, Carl P. LeBel, Ph.D. will be stepping down as the Company's Chief Development Officer, effective March 31, 2023.